IVELIP

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Soya Oil

Available from:

Baxter Healthcare Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

IVELIP 

  Consumer Medicine Information  

IVELIP CMI 010101                                 

          Page 1 of 3 
Baxter 

IVELIP 

WHAT IS IN THIS LEAFLET 

This leaflet answers some common questions
about IVELIP 20% [IVELIP
®
]. 

It does not contain all of 
the available information. All medicines have risks and benefit.
Your doctor has weighed the risks of you 
using IVELIP
® 
against the benefit he or she may expect it will have for you. 

It does not take the place of talking to your doctor
or pharmacist.  If you have any concerns about being 
administered this medicine, ask your doctor or pharmacist.  

Keep this leaflet with the medicine, as you may need to read
it again. 

WHAT IVELIP
® 
IS USED FOR AND HOW IT WORKS 

IVELIP
®
 is a sterile fat emulsion containing soya oil as an active component.  It is used as a source of 
energy and for correction of an essential fatty acids deficiency, and is given as an infusion directly into 
your  veins.  IVELIP
®
  is  intended  to  provide  you  with  nourishment (essential fatty acids) whilst  you are 
unable to consume food by mouth.  

Following an infusion of IVELIP, the fat and triglyceride component are released from the emulsion, and 
are subsequently broken down into fatty acid and glycerol in the liver. The free fatty acid is transported 
into muscle tissue, where it is converted into energy or transformed back into triglyceride and stored as a 
source of energy as fat in subcutaneous tissue    

BEFORE YOU ARE GIVEN IVELIP
®

IVELIP IV INFUSION SHOULD NOT BE GIVEN TO YOU IF: 
  you ha

Summary of Product characteristics

IVELIP 

Product Information 

IVELIP PI Amended 060124 

Page 1 of 10 
Baxter 

IVELIP 

NAME OF THE DRUG :  IVELIP
® 
20% 

COMPOSITION:  
Sterile fat emulsions containing refined soya oil 200 g,
egg lecithin (purified egg 
phospholipid) 12 g, glycerol 25 g, sodium oleate 0. 3
g and water for injection to 
1,000 mL (pH –6 - 8). The product does not contain
antibacterial agent. The active 
ingredient, soya oil, contains ascorbyl palmitate (0.15mg per gram
of oil) added as a 
free radical scavenger. 

DESCRIPTION:  
IVELIP has a consistency as milky white
emulsion. IVELIP 20% (w/v) has an 
osmolality of 350 mOsmol/kg water with energy content of 8360
kJ (2000 kcal) per 
1000 mL. The relative density of IVELIP is in the range of
0.919 – 0.925. IVELIP 
20% is an isotonic emulsion_. _

PHARMACOLOGY: 

_Pharmacodynamic properties_ - 
IVELIP
® 
20% is a lipid emulsion formulated as a source of energy to
be used together 
with carbohydrates and amino acids in parenteral nutrition.
 _IVELIP_
_®_
 also _provides_ 
essential fatty acids _and glycerol_. Egg lecithin supplies
phosphorous and choline. 
IVELIP
®
 emulsion is isotonic and provides a source of basal phosphate
requirements.  

IVELIP
®
 prevents essential fatty acid deficiency (EFAD) and corrects
the  
clinical manifestations of EFAD. For patients requiring complete
parenteral nutrition, 
complementary electrolyte, vitamin, and trace elements supplements
are required. 

_Pharmacokinetic properties_ - 
In IVELIP
®
, most of the lipid particle sizes are in the range of
the chylomicrons (0.08 
- 0.6 micrometers) with the mean diameter of less than 0.45
micrometer. However, it 
may contain a small fraction (up to 2.5%) of globules
of particles having diameter of 
more than 1.0 micrometer 

_Following IVELIP intravenous infusion, the lipid micelles interac